Life-threatening multiorgan immune-related toxicities complicated by sepsis after anti-PD-1 therapy with complete tumor regression: a case report and literature review - Takeaways - MDSpire

Life-threatening multiorgan immune-related toxicities complicated by sepsis after anti-PD-1 therapy with complete tumor regression: a case report and literature review

  • By

  • Jun Dong

  • Lijun Zhang

  • Lei Yu

  • Jun Wang

  • Jijie Huang

  • Xiaoyan Wu

  • Ping-An Wu

  • Suling Chen

  • Xixi Chen

  • Wenjuan Zhu

  • Yuan Qu

  • Jishi Li

  • Victor Ho Fun Lee

  • July 1, 2026

  • 0 min

Share

  • 1

    A 73-year-old man with sinonasal squamous cell carcinoma developed severe multisystem immune-related adverse events after anti-PD-1 treatment.

  • 2

    The patient experienced Stevens–Johnson syndrome, renal failure, pneumonitis, and recurrent sepsis, requiring intensive care.

  • 3

    Multidisciplinary management included corticosteroids and intravenous immunoglobulin (IVIG) to balance immune control and infection risk.

  • 4

    Despite life-threatening complications, the patient achieved complete tumor regression after one treatment cycle.

  • 5

    This case highlights the challenges of managing severe immune-related adverse events in patients receiving immune checkpoint inhibitors.

Original Source(s)

Life-threatening multiorgan immune-related toxicities complicated by sepsis after anti-PD-1 therapy with complete tumor regression: a case report and literature review

  • by Jun Dong, Lijun Zhang, Lei Yu, Jun Wang, Jijie Huang, Xiaoyan Wu, Ping-An Wu, Suling Chen, Xixi Chen, Wenjuan Zhu, Yuan Qu, Jishi Li, Victor Ho Fun Lee

  • July 1, 2026

Related Content

Overall survival and prognostic factors of oral cavity and oropharyngeal squamous cell carcinomas in Saudi Arabia: a population-based cohort study (2000–2019)

Conditional survival analysis May enhance prognosis estimate in buccal mucosa carcinoma

Host-microbiome-immune disequilibrium in oral disease: mechanisms, dysbiosis, and precision therapeutics